UK markets open in 2 hours 3 minutes

  • NIKKEI 225

    32,364.77
    -313.85 (-0.96%)
     

  • HANG SENG

    17,580.03
    -149.26 (-0.84%)
     

  • CRUDE OIL

    89.32
    -0.36 (-0.40%)
     

  • GOLD FUTURES

    1,932.70
    -3.90 (-0.20%)
     

  • DOW

    34,006.88
    +43.04 (+0.13%)
     

  • Bitcoin GBP

    21,576.87
    +160.42 (+0.75%)
     

  • CMC Crypto 200

    563.33
    +3.82 (+0.68%)
     

  • NASDAQ Composite

    13,271.32
    +59.51 (+0.45%)
     

  • UK FTSE All Share

    4,139.09
    -33.35 (-0.80%)
     
Crypto Mile:

Can web3 emulate the success of the $350bn traditional gaming market?

In Web3 gaming, players can earn cryptocurrency as they play as well as accumulate digital property

Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference

Merus N.V.
·1-min read
Merus N.V.
Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET.

The webcast of the panel discussion will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.


CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl  Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl